A critical review on the translational journey of cardioprotective therapies!

International Journal of Cardiology

Volumn 220, Issue , 2016, Pages 176-184

  Rossello, Xavier ^a   Yellon, Derek M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Ischemia reperfusion injury; Outcomes research; ST segment elevation myocardial infarction

Indexed keywords

ADENOSINE; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR AGENT; CYCLOSPORIN; EXENDIN 4; GLUCOSE; INSULIN; METOPROLOL; NICORANDIL; POTASSIUM; TRO 40303; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; COMORBIDITY; CONCOMITANT MEDICATION; DISEASE MARKER; DRUG MECHANISM; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; HYPOTHERMIA; ISCHEMIC POSTCONDITIONING; MORTALITY RATE; NONHUMAN; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRECLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMOTE ISCHEMIC CONDITIONING; REPRODUCIBILITY; REVIEW; ST SEGMENT ELEVATION; STUDY DESIGN; TIME TO TREATMENT; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; VALIDATION STUDY; ADVERSE EFFECTS; COMPLICATION; HEART FAILURE; MYOCARDIAL REPERFUSION INJURY; PROCEDURES; SECONDARY PREVENTION; ST ELEVATION MYOCARDIAL INFARCTION;

HEART FAILURE; HUMANS; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; ST ELEVATION MYOCARDIAL INFARCTION; VALIDATION STUDIES AS TOPIC;

EID: 84976869433     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.131     Document Type: Review

References (109)

1. [1] Keeley, E.C., Boura, J.A., Grines, C.L., Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003), 13–20, 10.1016/S0140-6736(03)12113-7.
2. [2] Yellon, D.M., Hausenloy, D.J., Myocardial reperfusion injury. N. Engl. J. Med. 357 (2007), 1121–1135, 10.1056/NEJMra071667.
3. [3] Maroko, P.R., Kjekshus, J.K., Sobel, B.E., Watanabe, T., Covell, J.W., Ross, J., et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43 (1971), 67–82.
4. [4] Heusch, G., Cardioprotection: chances and challenges of its translation. Lancet 381 (2013), 166–175, 10.1016/S0140-6736(12)60916-7.
5. [5] Lecour, S., Bøtker, H.E., Condorelli, G., Davidson, S.M., Garcia-Dorado, D., Engel, F.B., et al. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc. Res. 104 (2014), 399–411, 10.1093/cvr/cvu225.
6. [6] Rossello, X., Hall, A.R., Bell, R.M., Yellon, D.M., Characterization of the Langendorff perfused isolated mouse heart model of global ischemia–reperfusion injury: impact of ischemia and reperfusion length on infarct size and LDH release. J. Cardiovasc. Pharmacol. Ther., 2015, 10.1177/1074248415604462 (1074248415604462–).
7. [7] Fernández-Jiménez, R., Sánchez-González, J., Agüero, J., García-Prieto, J., López-Martín, G.J., García-Ruiz, J.M., et al. Myocardial edema after ischemia/reperfusion is not stable and follows a bimodal pattern. J. Am. Coll. Cardiol. 65 (2015), 315–323, 10.1016/j.jacc.2014.11.004.
8. [8] Lüscher, T.F., The bumpy road to evidence: why many research findings are lost in translation. Eur. Heart J. 34 (2013), 3329–3335, 10.1093/eurheartj/eht396.
9. [9] Jones, S.P., Tang, X.-L., Guo, Y., Steenbergen, C., Lefer, D.J., Kukreja, R.C., et al. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ. Res. 116 (2015), 572–586, 10.1161/CIRCRESAHA.116.305462.
10. [10] Pocock, S.J., Gersh, B.J., Do current clinical trials meet society's needs?. J. Am. Coll. Cardiol. 64 (2014), 1615–1628, 10.1016/j.jacc.2014.08.008.
11. [11] Rossello, X., Pocock, S.J., Julian, D.G., Long-term use of cardiovascular drugs. J. Am. Coll. Cardiol. 66 (2015), 1273–1285, 10.1016/j.jacc.2015.07.018.
12. [12] Yang, X.-M., Cui, L., Alhammouri, A., Downey, J.M., Cohen, M.V., Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc. Drugs Ther. 27 (2013), 403–412, 10.1007/s10557-013-6474-9.
13. [13] Eitel, I., Stiermaier, T., Rommel, K.P., Fuernau, G., Sandri, M., Mangner, N., et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur. Heart J., 2015, 10.1093/eurheartj/ehv463.
14. [14] Bell, R.M., Kunuthur, S.P., Hendry, C., Bruce-Hickman, D., Davidson, S., Yellon, D.M., Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection. Basic Res. Cardiol., 108, 2013, 331, 10.1007/s00395-013-0331-7.
15. [15] Cohen, M.V., Downey, J.M., Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br. J. Pharmacol. 172 (2015), 1913–1932, 10.1111/bph.12903.
16. [16] Bolli, R., Becker, L., Gross, G., Mentzer, R., Balshaw, D., Lathrop, D.A., Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ. Res. 95 (2004), 125–134, 10.1161/01.RES.0000137171.97172.d7.
17. [17] Bolli, R., Reflections on the irreproducibility of scientific papers. Circ. Res. 117 (2015), 665–666, 10.1161/CIRCRESAHA.115.307496.
18. [18] Wever, K.E., Hooijmans, C.R., Riksen, N.P., Sterenborg, T.B., Sena, E.S., Ritskes-Hoitinga, M., et al. Determinants of the efficacy of cardiac ischemic preconditioning: a systematic review and meta-analysis of animal studies. PLoS ONE, 10, 2015, e0142021, 10.1371/journal.pone.0142021.
19. [19] Lim, W.Y., Messow, C.M., Berry, C., Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis. Br. J. Pharmacol. 165 (2012), 2034–2043, 10.1111/j.1476-5381.2011.01691.x.
20. [20] Bulluck, H., Sirker, A., Loke, Y.K., Garcia-Dorado, D., Hausenloy, D.J., Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int. J. Cardiol. 202 (2016), 228–237, 10.1016/j.ijcard.2015.09.005.
21. [21] Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., Altman, D.G., Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol., 8, 2010, e1000412, 10.1371/journal.pbio.1000412.
22. [22] Ibáñez, B., Heusch, G., Ovize, M., Van de Werf, F., Evolving therapies for myocardial ischemia/reperfusion injury. J. Am. Coll. Cardiol. 65 (2015), 1454–1471, 10.1016/j.jacc.2015.02.032.
23. [23] Weintraub, W.S., Lüscher, T.F., Pocock, S., The perils of surrogate endpoints. Eur. Heart J. 36 (2015), 2212–2218, 10.1093/eurheartj/ehv164.
24. [24] Domanski, M., Pocock, S., Bernaud, C., Borer, J., Geller, N., Revkin, J., et al. Surrogate endpoints in randomized cardiovascular clinical trials. Fundam. Clin. Pharmacol. 25 (2011), 411–413, 10.1111/j.1472-8206.2010.00865.x.
25. [25] Bulluck, H., Yellon, D.M., Hausenloy, D.J., Reducing myocardial infarct size: challenges and future opportunities. Heart, 2015, 10.1136/heartjnl-2015-307855.
26. [26] Lønborg, J., Kelbæk, H., Vejlstrup, N., Bøtker, H.E., Kim, W.Y., Holmvang, L., et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ. Cardiovasc. Interv. 5 (2012), 288–295, 10.1161/CIRCINTERVENTIONS.112.968388.
27. [27] De Luca, G., Suryapranata, H., Ottervanger, J.P., Antman, E.M., Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109 (2004), 1223–1225, 10.1161/01.CIR.0000121424.76486.20.
28. [28] Gersh, B.J., Stone, G.W., White, H.D., Holmes, D.R., Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA 293 (2005), 979–986, 10.1001/jama.293.8.979.
29. [29] Miura, T., Miki, T., Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res. Cardiol. 103 (2008), 501–513, 10.1007/s00395-008-0743-y.
30. [30] P.M. Rothwell, External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 365 82–93 http://dx.doi.org/10.1016/S0140-6736(04)17670-8.
31. [31] Ibanez, B., Macaya, C., Sánchez-Brunete, V., Pizarro, G., Fernández-Friera, L., Mateos, A., et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri. Circulation 128 (2013), 1495–1503, 10.1161/CIRCULATIONAHA.113.003653.
32. [32] Roolvink, V., Ibanez, B., Ottervanger, J.P., Pizarro, G., van Royen, N., Mateos, A., et al. Early administration of intravenous beta blockers in patients with ST-elevation myocardial infarction before primary PCI. J. Am. Coll. Cardiol., 2016, 10.1016/j.jacc.2016.03.522.
33. [33] Bøtker, H.E., Kharbanda, R., Schmidt, M.R., Bøttcher, M., Kaltoft, A.K., Terkelsen, C.J., et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375 (2010), 727–734, 10.1016/S0140-6736(09)62001-8.
34. [34] Selker, H.P., Beshansky, J.R., Sheehan, P.R., Massaro, J.M., Griffith, J.L., D'Agostino, R.B., et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 307 (2012), 1925–1933, 10.1001/jama.2012.426.
35. [35] Pizarro, G., Fernández-Friera, L., Fuster, V., Fernández-Jiménez, R., García-Ruiz, J.M., García-Álvarez, A., et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). J. Am. Coll. Cardiol. 63 (2014), 2356–2362, 10.1016/j.jacc.2014.03.014.
36. [36] García-Ruiz, J.M., Fernández-Jiménez, R., García-Alvarez, A., Pizarro, G., Galán-Arriola, C., Fernández-Friera, L., et al. Impact of the timing of metoprolol administration during STEMI on infarct size and ventricular function. J. Am. Coll. Cardiol. 67 (2016), 2093–2104, 10.1016/j.jacc.2016.02.050.
37. [37] Pryds, K., Terkelsen, C.J., Sloth, A.D., Munk, K., Nielsen, S.S., Schmidt, M.R., et al. Remote ischaemic conditioning and healthcare system delay in patients with ST-segment elevation myocardial infarction. Heart, 2016, 10.1136/heartjnl-2015-308980 (heartjnl–2015–308980).
38. [38] Pocock, S.J., Clayton, T.C., Stone, G.W., Design of major randomized trials. J. Am. Coll. Cardiol. 66 (2015), 2757–2766, 10.1016/j.jacc.2015.10.036.
39. [39] Ovize, M., Thibault, H., Przyklenk, K., Myocardial conditioning: opportunities for clinical translation. Circ. Res. 113 (2013), 439–450, 10.1161/CIRCRESAHA.113.300764.
40. [40] Cung, T.-T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., et al. Cyclosporine before PCI in patients with acute myocardial infarction. N. Engl. J. Med., 373, 2015, 10.1056/NEJMoa1505489 150830000044009.
41. [41] Wang, D., Pocock, S., A win ratio approach to comparing continuous non-normal outcomes in clinical trials. Pharm. Stat., 2016, 10.1002/pst.1743.
42. [42] Pedersen, F., Butrymovich, V., Kelbæk, H., Wachtell, K., Helqvist, S., Kastrup, J., et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J. Am. Coll. Cardiol. 64 (2014), 2101–2108, 10.1016/j.jacc.2014.08.037.
43. [43] An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N. Engl. J. Med. 329 (1993), 673–682, 10.1056/NEJM199309023291001.
44. [44] Schwartz Longacre, L., Kloner, R.A., Arai, A.E., Baines, C.P., Bolli, R., Braunwald, E., et al. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 124 (2011), 1172–1179, 10.1161/CIRCULATIONAHA.111.032698.
45. [45] Whittington, H.J., Harding, I., Stephenson, C.I.M., Bell, R., Hausenloy, D.J., Mocanu, M.M., et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc. Res. 99 (2013), 694–704, 10.1093/cvr/cvt140.
46. [46] Szilvassy, Z., Ferdinandy, P., Nagy, I., Jakab, I., Koltai, M., The effect of continuous versus intermittent treatment with transdermal nitroglycerin on pacing-induced preconditioning in conscious rabbits. Br. J. Pharmacol. 121 (1997), 491–496, 10.1038/sj.bjp.0701163.
47. [47] Ferdinandy, P., Szilvássy, Z., Horváth, L.I., Csont, T., Csonka, C., Nagy, E., et al. Loss of pacing-induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. J. Mol. Cell. Cardiol. 29 (1997), 3321–3333, 10.1006/jmcc.1997.0557.
48. [48] Kyriakides, Z.S., Psychari, S., Iliodromitis, E.K., Kolettis, T.M., Sbarouni, E., Kremastinos, D.T., Hyperlipidemia prevents the expected reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Chest 121 (2002), 1211–1215.
49. [49] Ungi, I., Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. CHEST J., 128, 2005, 1623, 10.1378/chest.128.3.1623.
50. [50] Penna, C., Tullio, F., Moro, F., Folino, A., Merlino, A., Pagliaro, P., Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic Res. Cardiol. 105 (2010), 181–192, 10.1007/s00395-009-0075-6.
51. [51] Takeuchi, T., Ishii, Y., Kikuchi, K., Hasebe, N., Ischemic preconditioning effect of prodromal angina is attenuated in acute myocardial infarction patients with hypertensive left ventricular hypertrophy. Circ. J. 75 (2011), 1192–1199.
52. [52] Miki, T., Itoh, T., Sunaga, D., Miura, T., Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc. Diabetol., 11, 2012, 67, 10.1186/1475-2840-11-67.
53. [53] Ferdinandy, P., Schulz, R., Baxter, G.F., Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 59 (2007), 418–458, 10.1124/pr.107.06002.
54. [54] Sivaraman, V., Hausenloy, D.J., Wynne, A.M., Yellon, D.M., Preconditioning the diabetic human myocardium. J. Cell. Mol. Med. 14 (2010), 1740–1746, 10.1111/j.1582-4934.2009.00796.x.
55. [55] Ishihara, M., Inoue, I., Kawagoe, T., Shimatani, Y., Kurisu, S., Nishioka, K., et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J. Am. Coll. Cardiol. 38 (2001), 1007–1011.
56. [56] Mukhtar, O., Jackson, S.H., Drug therapies in older adults (part 1). Clin. Med. (Northfield. Il) 15 (2015), 47–53, 10.7861/clinmedicine.15-1-47.
57. [57] Ishihara, M., Sato, H., Tateishi, H., Kawagoe, T., Shimatani, Y., Ueda, K., et al. Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction. Am. Heart J. 139 (2000), 881–888.
58. [58] Marenzi, G., Cosentino, N., Cortinovis, S., Milazzo, V., Rubino, M., Cabiati, A., et al. Myocardial infarct size in patients on long-term statin therapy undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am. J. Cardiol. 116 (2015), 1791–1797, 10.1016/j.amjcard.2015.09.016.
59. [59] Whittington, H.J., Hall, A.R., McLaughlin, C.P., Hausenloy, D.J., Yellon, D.M., Mocanu, M.M., Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc. Drugs Ther. 27 (2013), 5–16, 10.1007/s10557-012-6425-x.
60. [60] Hausenloy, D.J., Whittington, H.J., Wynne, A.M., Begum, S.S., Theodorou, L., Riksen, N., et al. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc. Diabetol., 12, 2013, 154, 10.1186/1475-2840-12-154.
61. [61] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 373, 2015, 10.1056/NEJMoa1504720 150917085022006.
62. [62] Gross, E.R., Hsu, A.K., Gross, G.J., Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. J. Pharmacol. Exp. Ther. 310 (2004), 185–191, 10.1124/jpet.103.064667.
63. [63] Birnbaum, Y., Lin, Y., Ye, Y., Martinez, J.D., Huang, M.-H., Lui, C.Y., et al. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am. J. Physiol. Heart Circ. Physiol. 292 (2007), H2891–H2897, 10.1152/ajpheart.01269.2006.
64. [64] Sabatine, M.S., Cannon, C.P., Gibson, C.M., López-Sendón, J.L., Montalescot, G., Theroux, P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352 (2005), 1179–1189, 10.1056/NEJMoa050522.
65. [65] Montalescot, G., Wiviott, S.D., Braunwald, E., Murphy, S.A., Gibson, C.M., McCabe, C.H., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (London, England) 373 (2009), 723–731, 10.1016/S0140-6736(09)60441-4.
66. [66] Steg, P.G., James, S., Harrington, R.A., Ardissino, D., Becker, R.C., Cannon, C.P., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122 (2010), 2131–2141, 10.1161/CIRCULATIONAHA.109.927582.
67. [67] Cohen, M.V., Downey, J.M., Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J. Cardiovasc. Pharmacol. Ther. 19 (2014), 179–190, 10.1177/1074248413508465.
68. [68] Bell, R.M., Sivaraman, V., Kunuthur, S.P., Cohen, M.V., Downey, J.M., Yellon, D.M., Cardioprotective properties of the platelet P2Y12 receptor inhibitor, cangrelor: protective in diabetics and reliant upon the presence of blood. Cardiovasc. Drugs Ther. 29 (2015), 415–418, 10.1007/s10557-015-6609-2.
69. [69] Friedrichs, G.S., Kilgore, K.S., Manley, P.J., Gralinski, M.R., Lucchesi, B.R., Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ. Res. 75 (1994), 701–710.
70. [70] Black, S.C., Gralinski, M.R., Friedrichs, G.S., Kilgore, K.S., Driscoll, E.M., Lucchesi, B.R., Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc. Res. 29 (1995), 629–636, 10.1016/S0008-6363(96)88632-9.
71. [71] Antman, E.M., Morrow, D.A., McCabe, C.H., Murphy, S.A., Ruda, M., Sadowski, Z., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 354 (2006), 1477–1488, 10.1056/NEJMoa060898.
72. [72] Montalescot, G., Zeymer, U., Silvain, J., Boulanger, B., Cohen, M., Goldstein, P., et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 378 (2011), 693–703, 10.1016/S0140-6736(11)60876-3.
73. [73] Mehran, R., Lansky, A.J., Witzenbichler, B., Guagliumi, G., Peruga, J.Z., Brodie, B.R., et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet (London, England) 374 (2009), 1149–1159, 10.1016/S0140-6736(09)61484-7.
74. [74] Steg, P.G., van't Hof, A., Hamm, C.W., Clemmensen, P., Lapostolle, F., Coste, P., et al. Bivalirudin started during emergency transport for primary PCI. N. Engl. J. Med. 369 (2013), 2207–2217, 10.1056/NEJMoa1311096.
75. [75] O'Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Chung, M.K., de Lemos, J.A., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61 (2013), e78–140, 10.1016/j.jacc.2012.11.019.
76. [76] Bell, S.P., Sack, M.N., Patel, A., Opie, L.H., Yellon, D.M., Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J. Am. Coll. Cardiol. 36 (2000), 2296–2302.
77. [77] Birnbaum, G.D., Birnbaum, I., Y. Ye, Y., Birnbaum, statin-induced cardioprotection against ischemia–reperfusion injury: potential drug-drug interactions. lesson to be learnt by translating results from animal models to the clinical settings. Cardiovasc. Drugs Ther., 2015, 10.1007/s10557-015-6615-4.
78. [78] Puymirat, E., Lamhaut, L., Bonnet, N., Aissaoui, N., Henry, P., Cayla, G., et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) pr. Eur. Heart J. 37 (2016), 1063–1071, 10.1093/eurheartj/ehv567.
79. [79] Kubica, J., Adamski, P., Ostrowska, M., Sikora, J., Kubica, J.M., Sroka, W.D., et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur. Heart J. 37 (2016), 245–252, 10.1093/eurheartj/ehv547.
80. [80] Menees, D.S., Peterson, E.D., Wang, Y., Curtis, J.P., Messenger, J.C., Rumsfeld, J.S., et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 369 (2013), 901–909, 10.1056/NEJMoa1208200.
81. [81] Eapen, Z.J., Tang, W.H.W., Felker, G.M., Hernandez, A.F., Mahaffey, K.W., Lincoff, A.M., et al. Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. Circ. Cardiovasc. Qual. Outcomes. 5 (2012), 594–600, 10.1161/CIRCOUTCOMES.112.966150.
82. [82] Mandelzweig, L., The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur. Heart J. 27 (2006), 2285–2293, 10.1093/eurheartj/ehl196.
83. [83] Setoguchi, S., Glynn, R.J., Avorn, J., Mittleman, M.A., Levin, R., Winkelmayer, W.C., Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J. Am. Coll. Cardiol. 51 (2008), 1247–1254, 10.1016/j.jacc.2007.10.063.
84. [84] Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., Janzon, M., Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur. Heart J. 36 (2015), 1163–1170, 10.1093/eurheartj/ehu505.
85. [85] Mizumura, T., Nithipatikom, K., Gross, G.J., Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. Cardiovasc. Res. 32 (1996), 274–285.
86. [86] Kitakaze, M., Asakura, M., Kim, J., Shintani, Y., Asanuma, H., Hamasaki, T., et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370 (2007), 1483–1493, 10.1016/S0140-6736(07)61634-1.
87. [87] Grossman, A.N., Opie, L.H., Beshansky, J.R., Ingwall, J.S., Rackley, C.E., Selker, H.P., Glucose–insulin–potassium revived: current status in acute coronary syndromes and the energy-depleted heart. Circulation 127 (2013), 1040–1048, 10.1161/CIRCULATIONAHA.112.130625.
88. [88] Mehta, S.R., Yusuf, S., Díaz, R., Zhu, J., Pais, P., Xavier, D., et al. Effect of glucose–insulin–potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293 (2005), 437–446, 10.1001/jama.293.4.437.
89. [89] Yang, X.-M., Philipp, S., Downey, J.M., Cohen, M.V., Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res. Cardiol. 101 (2006), 311–318, 10.1007/s00395-006-0587-2.
90. [90] Liu, G.S., Thornton, J., Van Winkle, D.M., Stanley, A.W., Olsson, R.A., Downey, J.M., Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84 (1991), 350–356.
91. [91] Mahaffey, K.W., Puma, J.A., Barbagelata, N.A., DiCarli, M.F., Leesar, M.A., Browne, K.F., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Cardiol. 34 (1999), 1711–1720.
92. [92] Garcia-Dorado, D., García-Del-Blanco, B., Otaegui, I., Rodríguez-Palomares, J., Pineda, V., Gimeno, F., et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int. J. Cardiol. 177 (2014), 935–941, 10.1016/j.ijcard.2014.09.203.
93. [93] Heusch, G., Treatment of myocardial ischemia/reperfusion injury by ischemic and pharmacological postconditioning. Compr. Physiol. 5 (2015), 1123–1145, 10.1002/cphy.c140075.
94. [94] Thibault, H., Piot, C., Staat, P., Bontemps, L., Sportouch, C., Rioufol, G., et al. Long-term benefit of postconditioning. Circulation 117 (2008), 1037–1044, 10.1161/CIRCULATIONAHA.107.729780.
95. [95] Staat, P., Rioufol, G., Piot, C., Cottin, Y., Cung, T.T., L'Huillier, I., et al. Postconditioning the human heart. Circulation 112 (2005), 2143–2148, 10.1161/CIRCULATIONAHA.105.558122.
96. [96] Heusch, G., Bøtker, H.E., Przyklenk, K., Redington, A., Yellon, D., Remote ischemic conditioning. J. Am. Coll. Cardiol. 65 (2015), 177–195, 10.1016/j.jacc.2014.10.031.
97. [97] Hausenloy, D.J., Kharbanda, R., Rahbek Schmidt, M., Møller, U.K., Ravkilde, J., Okkels Jensen, L., et al. Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur. Heart J. 36 (2015), 1846–1848.
98. [98] Piot, C., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. 359 (2008), 473–481, 10.1056/NEJMoa071142.
99. [99] Ottani, F., Latini, R., Staszewsky, L., La Vecchia, L., Locuratolo, N., Sicuro, M., et al. Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial. J. Am. Coll. Cardiol. 67 (2016), 365–374, 10.1016/j.jacc.2015.10.081.
100. [100] Sonne, D.P., Engstrøm, T., Treiman, M., Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia–reperfusion injury in rat heart. Regul. Pept. 146 (2008), 243–249, 10.1016/j.regpep.2007.10.001.
101. [101] Timmers, L., Henriques, J.P.S., de Kleijn, D.P.V., Devries, J.H., Kemperman, H., Steendijk, P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53 (2009), 501–510, 10.1016/j.jacc.2008.10.033.
102. [102] Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H.E., Kim, W.Y., Mathiasen, A.B., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33 (2012), 1491–1499, 10.1093/eurheartj/ehr309.
103. [103] Ibanez, B., Prat-González, S., Speidl, W.S., Vilahur, G., Pinero, A., Cimmino, G., et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 115 (2007), 2909–2916, 10.1161/CIRCULATIONAHA.106.679639.
104. [104] Ibanez, B., Fuster, V., Reply: early intravenous beta-blockade before primary percutaneous coronary intervention gives major benefits apparently without side effects. J. Am. Coll. Cardiol. 64 (2014), 1864–1865, 10.1016/j.jacc.2014.08.013.
105. [105] Erlinge, D., A review of mild hypothermia as an adjunctive treatment for ST-elevation myocardial infarction. Ther. Hypothermia Temp. Manag. 1 (2011), 129–141, 10.1089/ther.2011.0008.
106. [106] Erlinge, D., Götberg, M., Lang, I., Holzer, M., Noc, M., Clemmensen, P., et al. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous cathete. J. Am. Coll. Cardiol. 63 (2014), 1857–1865, 10.1016/j.jacc.2013.12.027.
107. [107] Schaller, S., Paradis, S., Ngoh, G.A., Assaly, R., Buisson, B., Drouot, C., et al. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J. Pharmacol. Exp. Ther. 333 (2010), 696–706, 10.1124/jpet.110.167486.
108. [108] Hansson, M.J., Llwyd, O., Morin, D., de Paulis, D., Arnoux, T., Gouarné, C., et al. Differences in the profile of protection afforded by TRO40303 and mild hypothermia in models of cardiac ischemia/reperfusion injury. Eur. J. Pharmacol. 760 (2015), 7–19, 10.1016/j.ejphar.2015.04.009.
109. [109] Atar, D., Arheden, H., Berdeaux, A., Bonnet, J.-L., Carlsson, M., Clemmensen, P., et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur. Heart J. 36 (2015), 112–119, 10.1093/eurheartj/ehu331.